# eFFECTOR Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/effector-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.effector.com
- Total disclosed funding: $116M
- Latest round: Series C (Jul 24, 2017)
- Investors on record: 14

## About

Founded in 2012 and based in California, US, eFFECTOR Therapeutics, Inc. is a biopharmaceutical company that develops selective translation regulators drugs for the treatment of cancer and other serious diseases. The translation regulation helps to understand genes that are translationally dysregulated. Davide Ruggero, Kevan Shokat, Kevin Eastwood, Siegfried Reich, and Steve Worland are the co-founders of the company. In May 2021, the firm raised USD 60 million in PIPE funding from Abingworth, Alexandria Venture Investments, Altitude Funds, BioMed Ventures, OUP (Osage University Partners, Pfizer Venture Investments, Sectoral Asset Management, The Column Group, and US Venture Partners.

eFFECTOR’s lead product candidate, tomivosertib, is an MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivorsertib. The firm's second product candidate, Zotatifin, eFFECTOR’s small molecule inhibitor of eIF4A, is in the dose-escalation portion of a Phase 1/2 trial. The organization has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. The eFFECTOR’s product candidates are designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress, and inflammatory responses, as well as cell proliferation. The company's STRI (Selective Translation Regulator Inhibitor) product candidate targets the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). 

eFFECTOR plans to use the May 2021 funding to further develop its pipeline, report topline data from the randomized Phase 2b KICKSTART clinical trial of eFFECTOR’s lead product candidate, tomivorsertib. It will also use the funding to initiate multiple Phase 2a expansion cohorts for zotatifin and expansion of its products into additional indications.

## Funding rounds

- Series C, Jul 24, 2017, $39M — Abingworth, US Venture Partners, Novartis Venture Fund, SR One, Alexandria Venture Investments, Astellas Venture Management, The Column Group, Altitude Life Science Ventures, Pfizer Venture Investments, AbbVie Ventures, Sectoral Asset Management, BioMed Ventures
- Series B, Feb 19, 2016, $16M — Sectoral Asset Management
- Series B, Dec 22, 2015, $40M — Abingworth, US Venture Partners, Novartis Venture Fund, SR One, Astellas Venture Management, The Column Group, OUP (Osage University Partners), Altitude Life Science Ventures, Mission Bay Capital, AbbVie Ventures, BioMed Ventures
- Series A, Aug 13, 2014, $4.2M — Abingworth, US Venture Partners, Novartis Venture Fund
- Series A, May 15, 2013, $17M — Abingworth, US Venture Partners, Novartis Venture Fund, SR One, Astellas Venture Management, OUP (Osage University Partners), Mission Bay Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B, Series C
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A, Series B, Series C
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A, Series B
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series B, Series C
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series B, Series C
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B, Series C
- BioMed Ventures — Series B, Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series C